What alternative acute migraine medication can be used for a patient who develops palpitations while taking rizatriptan?

Switch to a Different Triptan First

For a patient experiencing palpitations with rizatriptan, the most appropriate initial alternative is to switch to a different triptan within the same class, as patients who do not tolerate one triptan may respond well to another with fewer side effects. 1

Rationale for Switching Within the Triptan Class

The 2025 American College of Physicians guideline explicitly states that "patients who do not tolerate or have inadequate response to a recommended migraine treatment may respond to another within the same drug class." 1 This is critical because:

• Triptans remain first-line therapy for moderate to severe migraine when combined with NSAIDs or acetaminophen
• Individual variability in triptan response and tolerability is well-documented 2
• Switching triptans has demonstrated success rates of 25-81% in patients who were poor responders or intolerant to their initial triptan 2

Specific Triptan Alternatives to Consider:

Naratriptan 2.5 mg or frovatriptan 2.5 mg are the best alternatives for this patient because:

• They have longer half-lives and slower onset, which correlates with better cardiovascular tolerability profiles
• Lower incidence of cardiovascular side effects including palpitations compared to faster-acting triptans like rizatriptan 3
• The FDA label for rizatriptan warns about cardiac arrhythmias and chest symptoms, which palpitations may represent 4

Alternative consideration: Almotriptan 12.5 mg or zolmitriptan 2.5 mg offer intermediate profiles between fast-acting and slower triptans 1, 5

Important Safety Caveat

Before switching, you must evaluate whether the palpitations represent a serious cardiac event. The rizatriptan FDA label warns that life-threatening arrhythmias including ventricular tachycardia and ventricular fibrillation have been reported with 5-HT1 agonists. 4

If the patient has:

• Multiple cardiovascular risk factors (age, diabetes, hypertension, smoking, obesity, strong family history of CAD)
• Any concerning cardiac symptoms beyond simple palpitations
• No prior cardiovascular evaluation

Then perform cardiovascular evaluation before prescribing any triptan. 4 Consider administering the first dose of the new triptan in a medically-supervised setting with ECG monitoring. 4

If All Triptans Are Not Tolerated

Should the patient fail to tolerate alternative triptans, the 2025 ACP guideline provides a clear escalation pathway 1:

1. CGRP antagonists (gepants): Rimegepant, ubrogepant, or zavegepant

   • These are recommended for patients who "do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen" 1
   • Gepants do not cause vasoconstriction, eliminating the cardiovascular mechanism responsible for palpitations with triptans
   • The 2024 VA/DoD guideline supports gepants with a "weak for" recommendation 6

2. Lasmiditan (ditan class): Reserved for patients who fail all other options 1

   • Also non-vasoconstrictive (5-HT1F agonist)
   • However, has significant CNS side effects including driving restrictions 6

3. Dihydroergotamine: An option but avoid if cardiovascular concerns exist, as ergots also cause vasoconstriction 1

Practical Algorithm

1. Assess cardiac risk: If palpitations were isolated and patient has no cardiac risk factors → proceed to step 2
2. Switch to naratriptan 2.5 mg or frovatriptan 2.5 mg as first alternative
3. If still intolerant → try almotriptan 12.5 mg or zolmitriptan 2.5 mg
4. If all triptans fail → switch to gepant (rimegepant or ubrogepant)
5. Ensure triptan + NSAID combination therapy for optimal efficacy 1

What NOT to Do

• Do not use opioids or butalbital for acute migraine treatment 1
• Do not continue rizatriptan if palpitations recur, as this may represent early cardiac toxicity 4
• Do not exceed 10 days/month of triptan use to avoid medication overuse headache 1